These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 11164715

  • 1. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
    Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clò V, Casolari B.
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
    [Abstract] [Full Text] [Related]

  • 2. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K.
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
    Tobinai K.
    Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
    [Abstract] [Full Text] [Related]

  • 4. 4. Antibody therapy for malignant lymphoma.
    Tobinai K.
    Intern Med; 2007 Jan; 46(2):99-100. PubMed ID: 17220608
    [Abstract] [Full Text] [Related]

  • 5. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V.
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA.
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.
    J Immunother; 2009 Aug; 32(6):622-31. PubMed ID: 19483647
    [Abstract] [Full Text] [Related]

  • 11. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK.
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K.
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [Abstract] [Full Text] [Related]

  • 14. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C, DeNardo G, Tobin E, DeNardo S.
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.